Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Transmission of Behavioral Deficits in Rats Exposed to Folate Receptor Alpha Antibody In Utero.
Child Neurology and Developmental Neurology
S2 - Child Neurology and Developmental Neurology 1 (1:00 PM-1:12 PM)
001

Folate deficiency is known to lead to disruptions in neurodevelopment including neural tube defects and developmental anomalies such as ASD. Folate receptor alpha (FRα) is the main transporter of folate from the mother to the fetus and into the brain. A major subset of the ASD population and their family members have autoantibodies against FRα that may cause neuroinflammation and block folate transport to the developing fetus.

We aim to investigate the behavioral deficits in rats exposed to folate receptor alpha antibodies (FRaAb) during fetal development. Furthermore, we aim to investigate the heritability of this autism spectrum disorder (ASD)-like phenotype by determining whether it is transmitted to a subsequent generation. 

Our laboratory has produced rat FRα specific antibody (FRαAb) that when injected intraperitoneally into a dam on gestation day 8, will produce a litter with ASD-like behavioral deficits. This phenotype can be prevented when the dam is given D, L-folinic acid, dexamethasone, or a combination of both at the time of FRαAb exposure. We tested both the litter directly exposed to FRαAb and the offspring of those with an affected phenotype using a battery of social and learning tests.
We observed deficits in social communication, social interaction, learning and memory in both the first and second generations which suggests transmission of the behavioral phenotype associated with FRαAb exposure.
The intergenerational transmission of this phenotype to animals not directly exposed to FRαAb suggests that it may be mediated by epigenomic changes. We hypothesize that treatment of the directly exposed generation with folinic acid prior to mating may prevent transmission of behavioral deficits to a subsequent generation by altering the epigenome. This may be a strategy to decrease the risk in families with a history of ASD.
Authors/Disclosures
Jonathan R. Amaro-Barron, MD (Michigan Medicine)
PRESENTER
Dr. Amaro-Barron has nothing to disclose.
Natasha Bobrowski-Khoury, PhD (Mass General Hospital/Harvard Medical School) Ms. Bobrowski-Khoury has nothing to disclose.
No disclosure on file